FIBROBODY
Live / Registered — Registered (as of 25 Jan 2022)
What this means for you
Registered since 25 Jan 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79321550
- Registration number
- 6624524
- Mark type
- Stylized text
- Filed
- 18 Feb 2021
- Published for opposition
- 09 Nov 2021
- Registered
- 25 Jan 2022
Goods and services
- Class 001 — Chemicals: Chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals for treating fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and per-oral formulations, tablets and capsules that facilitate the delivery of pharmaceutical preparations; pharmaceutical drugs for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and per-oral formulations, tablets and capsules that facilitate the delivery of pharmaceutical preparations; biochemical medicines for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; chemical preparations for pharmaceutical purposes, namely, for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; diagnostic agents for pharmaceutical purposes; pharmaceutical substances and preparations for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents consisting of compounds that facilitate delivery of pharmaceutical preparations
- Class 042 — Scientific and technological services: Pharmaceutical research services; conducting clinical trials for others relating to pharmaceuticals; pharmaceutical research and development; pharmaceutical product evaluation; consultancy relating to pharmaceutical research and development; laboratory research services relating to pharmaceuticals; providing information about the results of clinical trials for pharmaceuticals; providing information about medical and scientific research in the field of pharmaceuticals; scientific research services in the field of proteins, antibodies, microorganisms and cells; research and development services in the field of antibody technology; design and development of medical technology
- Class 044 — Medical, beauty and agricultural services: Medical services, namely, in vitro analysis for medical and pharmaceutical use; medical services, namely, in vitro testing for medical and pharmaceutical use; consultancy and information services provided via the internet relating to pharmaceutical products
Owner
- LinXis B.V., NL
- LinXis B.V., NL
- LinXis B.V., NL
Prosecution history
- 19 Sept 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 14 Mar 2025 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 20 Sept 2024 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 05 Jun 2022 — NOTIFICATION PROCESSED BY IB
- 19 May 2022 — FINAL DISPOSITION NOTICE SENT TO IB
- 18 May 2022 — FINAL DISPOSITION PROCESSED
- 24 Feb 2022 — GRANT OF PROTECTION CREATED, TO BE SENT TO IB
- 25 Jan 2022 — REGISTERED-PRINCIPAL REGISTER
- 09 Nov 2021 — PUBLISHED FOR OPPOSITION
- 20 Oct 2021 — NOTICE OF PUBLICATION
- 12 Oct 2021 — APPLICATION FILING RECEIPT MAILED
- 06 Oct 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 06 Oct 2021 — ASSIGNED TO EXAMINER
- 06 Oct 2021 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 04 Oct 2021 — LIMITATION FROM ORIGINAL APPLICATION ENTERED